PDGFRB and colorectal carcinoma: In pre-clinical studies, inhibition of PDGFR/KIT signaling reduces tumor cell invasion and metastatic potential in models of mesenchymal-like CRC (7, 8, 11) and other cancer types (12–14), suggesting that imatinib may have value as a CMS4-targeting drug.